Headaches, Vision Changes, and Odd Hormones: Pituitary Adenoma
Most people do not find their own pituitary tumour. A visual field machine finds it, or a hormone panel ordered for something else, or an MRI done for headaches. The gland is the size of a pea and sits at the base of the brain, and its output sets the thyroid, the adrenal glands and the sex glands (per MedlinePlus). So nothing that grows there stays local. Something that small can take the outer half of the vision in both eyes and rearrange a dozen hormone values at the same time. Reading the field result, the hormone numbers and the scan as one case rather than three appointments is the job Healz's memory was built for.
This post walks the finding the way it is actually worked up: what the pituitary controls, where the size line sits, which tumours make hormones and which do not, why peripheral vision goes before central vision, and what the tests are for. One of these tumours is an emergency. The rest are a workup.

What a gland the size of a pea is actually in charge of
The pituitary is a small gland at the base of the brain that regulates many hormones, and it influences other glands including the thyroid, the sex glands and the adrenal glands, releasing hormones such as growth hormone and prolactin (per MedlinePlus). It sits just above the sphenoid bone, the butterfly-shaped bone at the base of the skull (per the NCI). That is a crowded, bony compartment with the optic nerves directly overhead.
Two consequences follow. First, a tumour that would be unremarkable almost anywhere else in the body is loud here, because the structures it can lean on are the optic nerves and the gland itself. Second, the symptoms arrive in two completely different languages. One is mechanical: headache, vision loss, falling hormone levels because the normal gland is being squeezed. The other is biochemical: one hormone pouring out in excess while the person has no neurological symptom at all.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
Pituitary tumours are also common, and most are quiet. Adenomas make up the largest share of pituitary tumours with an overall estimated prevalence of about 17% (per the NCI), and MedlinePlus puts the figure at up to 10% to 20% of people, noting that many never cause symptoms. Those figures count every adenoma found, including the ones picked up by accident on a scan ordered for something else; the tumours that actually declare themselves are far rarer, occurring in approximately 1 in 1,100 persons (JAMA 2023). Most are noncancerous.
Microadenoma or macroadenoma, and why that one word changes the story
The classification is blunt and useful. Tumours are divided into microadenomas, meaning a greatest diameter under 10 mm, and macroadenomas, meaning 10 mm or larger (per the NCI). About 48% of pituitary adenomas are macroadenomas (JAMA 2023). One centimetre is an arbitrary-looking line that tracks something real: whether a tumour can reach what sits above the gland.
So the size word is a shorthand for which problem is in front of you. A microadenoma, if it causes trouble at all, causes it by what it secretes. A macroadenoma can do that too, but it can also produce mass effect, meaning visual field defects, headache and hypopituitarism, which is the failure of the normal gland's output (JAMA 2023).
The size also decides who gets which evaluation. Every patient needs an endocrine evaluation for hormone hypersecretion; patients with macroadenomas additionally need evaluation for hypopituitarism, and patients whose tumours compress the optic chiasm should be seen by an ophthalmologist for formal visual field testing (JAMA 2023). Microadenoma and macroadenoma on a report are starting two different workups.
Functioning, non-functioning, and the one tumour that is not operated on first
A functioning tumour secretes a hormone. A non-functioning one does not, and announces itself only by size or by crowding out the rest of the gland. Functionally inactive pituitary adenomas make up approximately 30% to 35% of pituitary tumours in most series (per the NCI), and JAMA 2023 puts non-functioning tumours at about 30%.
Among the ones that do secrete, prolactinomas are the most common, around 53% of pituitary adenomas, and they cause hypogonadism, infertility or galactorrhoea (JAMA 2023). Growth hormone secreting tumours, somatotropinomas, are about 12% and cause acromegaly in adults and gigantism in children. ACTH secreting tumours, corticotropinomas, are about 4% and drive hypercortisolaemia and Cushing disease (JAMA 2023). Thyrotropin secreting tumours exist and are rarer.
For pituitary adenomas in general, transsphenoidal surgery is usually the first-line treatment, but prolactinomas are the exception: medical therapy with bromocriptine or cabergoline is usually first-line (JAMA 2023). These are dopamine agonists, and the NCI states that most microprolactinomas and macroprolactinomas respond well to medical therapy with ergot-derived dopamine agonists. A tablet that shrinks a brain tumour reads like a mistake on the page, and it is the standard. Which is why the single most consequential line in a pituitary workup is often not the tumour size but which hormone is high. For the cortisol side of that question, our piece on cortisol and adrenal testing covers how that axis gets measured and misread.
Why the outer half of your vision goes first
The optic nerves from both eyes meet above the pituitary at the optic chiasm, and the fibres that cross there are the ones carrying the outer, temporal half of each eye's field. Compression of the chiasm from below generates significantly elevated tissue pressure in the central portion of the chiasm, where those crossing fibres run, so it is the crossing fibres corresponding to the temporal hemifield that are mainly damaged (Clinical Ophthalmology 2020). The result is the pattern named bitemporal hemianopia.
Central vision, the part you use to read and to check whether your eyes are fine, is usually spared longest, and the edges fade without announcing it, because the brain fills in from the other eye and from the parts of the field that still work. The loss is rarely tidy: asymmetric visual field defects between the two eyes are common, a complete symmetrical bitemporal hemianopia is uncommon, and severe scotomas cluster in the upper temporal and lower nasal quadrants (Kotoda et al., Clinical Ophthalmology 2020;14:317-324). Visual field defects are listed among the common presenting symptoms of pituitary adenoma (per the NCI), and JAMA 2023 reports them in roughly 18% to 78% of patients with macroadenomas, a range wide enough to say plainly that it depends heavily on who is being measured and how.
Headache is the other mechanical symptom, and on its own it is a weak signal, because almost everyone has headaches and almost no one has a pituitary tumour. What raises the question is a headache sitting beside something else: a field defect, an unexplained hormone value, a change in periods or libido or energy. Our guide to headache red flags and brain tumours covers which features actually move a headache into imaging territory.
What makes the diagnosis, and the one version that is an emergency
Three things, read together. Hormone measurement, because the biochemistry names the tumour type: MedlinePlus lists ACTH, growth hormone, IGF-1, prolactin and TSH among the tests, alongside a brain MRI. Formal visual field testing, when the lesion reaches the chiasm (JAMA 2023). And imaging, where the detail matters, because the pituitary is small and a microadenoma can sit below what a general brain series resolves, which is why the scan is usually requested as a dedicated pituitary study rather than a routine brain scan.
Then there is the acute version. Pituitary apoplexy is a clinical syndrome characterised by the sudden onset of headache, vomiting, visual impairment and decreased consciousness, caused by haemorrhage or infarction of the pituitary gland (UK guidelines for the management of pituitary apoplexy, Clinical Endocrinology 2011). The same guidelines state that classical pituitary apoplexy is a medical emergency and that rapid replacement with hydrocortisone may be life saving. It can be the first sign of a tumour nobody knew was there, which is why it is taught as its own entity.
For tumours that do need an operation, the transsphenoidal microsurgical approach is the most widely used, reaching the gland through the nose and the sphenoid bone (per the NCI), and progressive deterioration of the visual fields is often the primary neurological criterion for going ahead.
How Healz reads a field test, a hormone panel and an MRI as one case
A pituitary workup is three documents written by three specialists who may never read each other's. The field test lives with the ophthalmologist. The prolactin and cortisol values live in a lab portal. The MRI report lives with whoever ordered it. Each one alone is ambiguous. Together they are usually obvious.
Healz is equipped with memory, and that is what closes the gap. It pulls the medical facts out of every upload, dates each one, keeps the abnormal values up front, and connects them across months, so this year's field test sits beside last year's and the prolactin line is a trend rather than a single number. Frontier AI works the whole file in one chat, not ten apps and four portals. As an ai mri analysis and blood test ai analyzer in the same place, it reads the imaging report against the hormone panel instead of either one in isolation. Healz is also equipped with root-cause technology: it does not stop at the first label, asks what a rushed fifteen-minute visit skips, and cross-checks the case against more than a million rare cases, so a high prolactin from a tumour is separated from a high prolactin with another explanation rather than assumed. When you want a human reading it too, you can bring a board-certified doctor into the same chat for a second opinion.
Frequently asked questions
- Is a pituitary adenoma cancer?
Almost always no. Most pituitary tumours are noncancerous (per MedlinePlus). The NCI groups pituitary tumours by biological behaviour into benign adenoma, invasive adenoma and carcinoma, and notes that approximately 35% of pituitary adenomas are invasive, meaning they may invade the dura mater, cranial bone or sphenoid sinus. The terminology did change: the 2022 WHO classification files these well-differentiated tumours as pituitary neuroendocrine tumours, or PitNETs, formerly known as pituitary adenomas, and replaces the term pituitary carcinoma with metastatic PitNET (Asa, Mete, Perry and Osamura, Endocrine Pathology 2022). Both names refer to the same tumour.
- What size pituitary tumour is serious?
Size is one axis, not the whole answer. The dividing line is 10 mm, under which a tumour is a microadenoma and at or above which it is a macroadenoma (per the NCI), and macroadenomas are the ones that can produce mass effect such as visual field defects, headache and hypopituitarism (JAMA 2023). A small tumour secreting a lot of hormone can matter more than a larger quiet one.
- Can a pituitary tumour cause vision loss?
Yes, by compressing the optic chiasm that sits directly above the gland. Because the fibres crossing at the chiasm carry the outer half of each eye's field, the characteristic loss is bitemporal, and usually asymmetric between the two eyes rather than a matching pair (Clinical Ophthalmology 2020). Central vision is usually spared longest. Visual field defects are reported in roughly 18% to 78% of patients with macroadenomas (JAMA 2023).
- Does a prolactinoma always need surgery?
No, and this is the main exception in pituitary treatment. Transsphenoidal surgery is usually first-line for pituitary adenomas, but for prolactinomas medical therapy with bromocriptine or cabergoline is usually first-line (JAMA 2023), and the NCI notes that most microprolactinomas and macroprolactinomas respond well to ergot-derived dopamine agonists.
A pea-sized gland with the optic nerves overhead is a small target with outsized consequences, and the finding almost never arrives as one clean result. It arrives as a field test, a hormone value and a scan, written by three people who did not see each other's.
Written by Healz Team · Filed under Health Insights